In open-chest dogs, cyclic flow reductions (CFRs, 5.1-6.6/hr in controls; n=24) caused by platelet deposition/dislodgment at sites of endothelial cell injury in critically stenosed left anterior descending coronary arteries (59%o flow reduction) were attenuated to the same extent either by single thromboxane A2 (TXA2) synthase inhibition (0.31 mg/kg i.v. ridogrel; CFR, 0.16+0.16/hr, n=6; p<0.05) or by a comparatively modest degree of TXA2/prostaglandin endoperoxide receptor antagonism on top of TXA2 synthase inhibition (5 mg/kg i.v. ridogrel; CFR, 0.22 +0.1/hr, n=10; p<0.05). By contrast, occlusive thrombosis on deep vascular damage elicited by intraluminal stimulation (150-,uA anodal constant current) in nonpreconstricted canine coronary arteries (time to occlusion, 237.1±+13.9 minutes; n=7; incidence of occlusion within 300 minutes, six of seven experiments) was not affected by platelet cyclooxygenase inhibition (5 mg/kg i.v. acetylsalicylic acid; n=7), single TXA2 synthase inhibition (1.25 mg/kg i.v. ridogrel; n=7), or single TXA2/prostaglandin endoperoxide receptor antagonism (10 mg/kg+10 mg/kg/hr i.v. sulotroban for 300 minutes; n=5). However, such an occlusive thrombus formation was significantly reduced by combined TXA2 synthase/prostaglandin endoperoxide receptor inhibition (5 mg/kg i.v. ridogrel; time to occlusion >300 minutes, n=7; incidence of occlusion within 300 minutes, one of seven experiments; p<0.05). This study reveals 1) a differential efficacy of TXA2 synthase inhibition, singly or combined with TXA2/prostaglandin endoperoxide receptor antagonism, depending on the extent of the vessel wall lesion triggering thrombosis and the size of the thrombus required to obstruct the vascular lumen and 2) a significant synergism in preventing occlusive thrombosis of extensively damaged coronary arteries between strong TXA2 synthase inhibition and comparatively modest TXA2/prostaglandin endoperoxide receptor antagonism with ridogrel. (Circulation Research 1991;69:313-324) rterial thrombus formation is a complex proand release several mediators from their storage 
These observations suggest a differential dominance in modulating thrombus formation of platelet-agonistic mediators, such as prostaglandin endoperoxides and TXA2, in comparison with that of platelet-inhibitory prostanoids generated after TXA2 synthase inhibition. Such a difference seems to depend on the magnitude of the arterial wall lesion initiating the thrombotic process as well as on the size of the damaged vessel lumen to be thrombotically occluded. It may determine the potential value of drug administration as an antithrombotic principle, particularly when extensive arterial wall damage rather than discrete endothelial cell injury is causing the thrombotic process.
Therefore, we evaluated the effects of TXA2 synthase inhibition, singly and in combination with TXA2/ prostaglandin endoperoxide receptor antagonism, against thrombus formation elicited by endothelial cell injury in critically stenosed canine coronary arteries17 and compared them with effects of TXA2 synthase inhibition against occlusive thrombosis elicited by deep vessel wall injury in nonpreconstricted canine coronary arteries. 22, 25 For that purpose, ridogrel was used either in low doses, mainly producing specific TXA2 synthase inhibition, or in a higher dose, providing additional TXAJprostaglandin endoperoxide receptor antagonism.26,27 We compared the antithrombotic potential of such pharmacological manipulations with the antithrombotic potential of cyclooxygenase inhibition provided by acetylsalicylic acid17 and of single TXA2/ prostaglandin endoperoxide receptor blockade obtained with sulotroban.28 29 
Materials and Methods

Experimental Preparation
The study was performed in 86 anesthetized mongrel dogs of both sexes, weighing 20-42 kg (median, 26 kg), enrolled in three experimental scenarios.
To 26, 27 In some cases, immediately after the dog was killed with an overdose of pentobarbital, the constricted artery was removed and fixed for at least 24 hours in Karnovsky's fixative consisting of 2% formaldehyde and 2.5% glutaraldehyde in 0.1 M phosphate buffer, pH 7.4. After rinsing in phosphate buffer supplemented with 7.5% sucrose, postfixation in 2% osmium tetroxide buffered to pH 7.4 with veronal acetate, and impregnation in 0.5% uranium acetate, the vessel segments were dehydrated in graded series of ethanol and routinely embedded in Epon. Toluidine blue-stained sections then were examined by light microscopy.
To evaluate pharmacological effects on occlusive thrombus formation elicited by deep intimal injury in nonpreconstricted coronary arteries22,25 in anesthetized dogs,32 the heart was exposed by a left thoracotomy and suspended in a pericardial cradle. The LAD, just distal from the offspring of the left circumflex artery, was isolated from surrounding tissues and equipped with a precalibrated electromagnetic flow probe connected to a square-wave electromagnetic flowmeter. Zero-flow baseline values of CBF were established by inducing a transient, total occlusion by means of a ligature (Mersilk 4.0); the reactive hyperemia in response to such a 30-second total occlusion was determined as well. The electrocardiogram was derived from limb leads (lead II) and HR was computed from the electrocardiogram using a cardiotachometer (Janssen Scientific Instruments Division). Thereafter, a stainless-steel stimulation electrode (0.5 -mm diameter) connected to the anodal pole of a constant current generator (Janssen Scientific Instruments Division) was inserted through the wall of the LAD about 1 cm distal to the flow probe and oriented to make contact with the intimal lumen surface of the vessel.25 A cathodal electrode was attached to the exposed thoracic muscles. After a 20-minute stabilization period and continuous recording of baseline values, solvent or compound solution was administered intravenously. Ten minutes later, electrical stimulation (anodal constant current of 150 ,A) of the LAD was initiated and continued for 300 minutes or until the CBF declined to zero. Patency or occlusion of the vessel was confirmed by measuring the reactive hyperemic response to a 30-second total occlusion. Thereafter, the heart was quickly excised, the LAD was opened over its full length, the thrombus was quantitatively removed and weighed (mg), and the wet thrombus lated. Venous blood was sampled during the stabilization period and again at the end of the experiment and was processed for the determination of serum thromboxane B2 (TXB2) levels. 26, 27 In a separate group of solvent-treated dogs subjected to intraluminal anodal stimulation, the coronary vessel was removed immediately after thrombotic occlusion and processed for light microscopical examination without removing the thrombus.
Experimental Protocols
To document the dose-related effects of ridogrel on TXA2 synthase activity and on TXAjprostaglandin endoperoxide receptors in anesthetized dogs, venous blood was sampled 5 minutes before the injection of To assess influences on platelet deposition/dislodgment at sites of endothelial cell injury in critically stenosed coronary arteries, CFR and hemodynamic parameters were registered for 1 hour to provide baseline values. Thereafter, solvent (n=8) or 0.31 mg/kg (n=6) or 5 mg/kg (n=10) ridogrel was administered intravenously, and CFR frequency (incidences per hour) and hemodynamic parameters were recorded for an additional 180 minutes. CFR frequency and hemodynamic parameters in solvent-or ridogreltreated dogs were compared with those before treatment; changes after administration of ridogrel were also compared with those after solvent. Serum levels of TXB2 after solvent or ridogrel were compared with those in pretreatment samples. Ten and 180 minutes after the administration of ridogrel, venous blood samples were obtained and processed for the determination of plasma levels of the compound.
To document pharmacological modification of occlusive thrombus formation elicited by deep intimal injury of nonpreconstricted coronaries, appropriately instrumented dogs were treated intravenously with weight/heart weight ratio (mgx 100/g) was calcusolvent (n=7), 1 .25 mg/kg (n=7) or 5 mg/kg (n=7) ridogrel, 5 mg/kg acetylsalicylic acid (n=7), or a 10 mg/kg bolus injection of sulotroban followed by a continuous infusion of 10 mg/kg/hr for 300 minutes (n =5). Fifteen minutes later, electrical stimulation of the LAD was initiated and continued for 300 minutes or until complete occlusion of the vessel occurred. Changes in hemodynamic parameters relative to baseline readings in compound-treated dogs were compared with changes in solvent-treated dogs. Levels of TXB2 in sera obtained after the administration of solvent or compounds were compared with levels in pretreatment samples. Ten and 180 minutes after the intravenous injection of 5 mg/kg ridogrel, venous blood was collected and processed for the determination of plasma levels of the compound.
Serum Prostanoid Determinations
For the determination of serum prostanoid levels, venous whole blood (1.6 ml) anticoagulated with Na3 citrate 2H20 (0.38%) was warmed to 37°C (10 minutes) and coagulated (1 hour at 37°C) by the addition of 0.2 ml CaCl2 (X 10-3 M final concentration) and 0.2 ml thrombin (20 NIH units/ml final concentration). Thereafter, cell-free serum was prepared by repeated centrifugations (15 minutes at 350g, 5 minutes at 10,000g) and stored at -25°C. Serum levels (ng/ml) of TXB2 (nonextracted samples) were determined by radioimmunoassay, using specific antisera and tritiated tracers.26,27 Plasma levels of ridogrel (,g/ml) were determined by high-performance liquid chromatography. They were recalculated (,uM), taking into account the molecular weight (366) of ridogrel.26 Platelet TX42/Prostaglandin Endoperoxide Receptor Antagonism
To assess the antagonism by ridogrel of canine platelet TXAJprostaglandin endoperoxide receptors at plasma levels of the compound achieved after in vivo administration, inhibition of canine platelet aggregation, triggered by U46619 after presensitization with L-epinephrine, by various compound concentrations was measured in vitro.33 For that purpose, 0.4 ml platelet-rich plasma (3 x 105 cells/,ll) prepared from citrated, venous blood was incubated (10 minutes at room temperature and 5 minutes at 37°C) with 0.05 ml HEPES buffer (200 mM, pH 7.5) and 0.05 ml solvent (0.15 M NaCl) or ridogrel solution (1-100 ,uM), supplemented with 0.01 ml L-epinephrine (10 ,uM, 2 minutes at 37°C) before the addition of 10 Ill U46619 (1 ,M) to the stirred sample. The extent of the platelet response was quantified by measuring the maximal increase in light transmission on the aggregation tracings. Percentages of inhibition of U46619-triggered platelet aggregation by ridogrel were calculated versus reactions in the paired solvent-treated samples. (Figure 1 ). Statistical analysis of nary constrictor around the LAD reduced CBF to the same extent in all three experimental groups (41.2±3.6% of baseline values, n=24) and resulted in a similar incidence of CFR (between 5.1 and 6.6 CFR/hr) during the 1-hour observation period before treatment (Figure 2 ). During that observation period, HR, AoPs, AoPd, and LVEDP remained fairly stable (Figure 3) .
After injection of solvent, the frequency of CFR remained unchanged (5.1±0.6/hr, n=8) relative to that in the pretreatment period (5.7±0.8/hr) ( Figure  3 ). AoPs and AoPd remained constant, HR slightly decreased, but LVEDP increased significantly after an additional 15 minutes of CFR to remain elevated throughout the 180-minute observation period (Figure 3 Figure  2 ). Changes in HR, AoPs, and AoPd after both doses of ridogrel were similar to the ones observed after solvent administration. However, the increase of LVEDP that persisted after treatment with solvent or 0.31 mg/kg i.v. ridogrel did not occur after the administration of 5 mg/kg i.v. ridogrel ( Figure 3) .
Light microscopic examination of LAD segments at the site of the constrictor taken from solventtreated (n=4) and compound-treated (n=7) dogs revealed a desquamation of the endothelial cell layer and an exposure of subendothelial tissue. In the solvent-treated group (Figure 4a) hyperemic response to a 30-second occlusion were similar in all groups (Table 3) . In solvent-treated dogs, intraluminal anodal stimulation resulted in an occlusion of the LAD after 237.1 + 13.9 minutes of continuous electrical challenge. This was evidenced by the cessation of CBF, the loss of reactive hyperemia, the appearance of arrhythmias and ST changes in the electrocardiogram indicative of myocardial ischemia, and the presence of an obstructive coronary thrombus at autopsy (Table 3) .
Microscopic analysis of coronary artery segments at the site of electrode insertion revealed the presence of extensive transmural vessel wall damage and the development of occlusive thrombi consisting mainly of aggregated platelets intermingled with fibrin threads and entrapped red blood cells (Figure 4b of ridogrel but were only marginally affected by sulotroban (Table 3) . Hemodynamic parameters, in particular CBF, before initiation of coronary artery electrical stimulation were not significantly modified by the administration of the compounds in comparison with premedication values.
Discussion
The present study reveals differential effects of TXA2 synthase inhibition singly or combined with TXA2/prostaglandin endoperoxide receptor antagonism on occlusive thrombus formation elicited by endothelial cell injury or by deep vessel wall damage in canine coronary arteries. This difference depends at least on two factors: 1) the magnitude of the vessel wall lesion initiating the thrombotic process and 2) the amount of thrombotic material required for vascular obstruction, as determined by the size of the vessel lumen to be obstructed in order to cause a cessation of blood flow.
In our first model, the endothelial cell layer is disrupted by manipulation of the coronary artery, exposing subendothelial tissue; this elicits platelet deposition at the site of the vascular lesion as documented by morphological observations (the present study and Reference 17) and by measurements with radiolabeled platelets.21 In the presence of a mechanically imposed critical stenosis reducing the lumen of the vessel by >90% and blood flow by -50%, the deposition of comparatively small amounts of platelets at the site of the endothelial cell lesion obstructs the remaining vessel lumen, causing cessa- 
